Loss of CDC14B Expression in Clear Cell Renal Cell Carcinoma Meta-Analysis of Microarray Data Sets
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Younghye | - |
dc.contributor.author | Choi, Jung-Woo | - |
dc.contributor.author | Lee, Ju-Han | - |
dc.contributor.author | Kim, Young-Sik | - |
dc.date.accessioned | 2021-09-05T10:09:03Z | - |
dc.date.available | 2021-09-05T10:09:03Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-04 | - |
dc.identifier.issn | 0002-9173 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/98882 | - |
dc.description.abstract | Objectives: To discover significant differentially expressed genes (DEGs) in clear cell renal cell carcinoma (ccRCC) that might be unidentified by single microarray analysis. Methods: The effect sizes of five ccRCC microarray data sets were combined using a random-effects model. The most downregulated gene was validated in paired 80 ccRCC tissues by immunohistochemistry. Results: CDC14B was the most downregulated gene among 1,761 DEGs. CDC14B was strongly expressed in the apical proximal tubules in the nonneoplastic tissues, while it was completely absent in 10 (12.5%) of 80 or downregulated in 70 (87.5%) of 80 ccRCC cases. The complete loss of CDC14B correlated with high T stage (P = .038), advanced TNM stage (P = .027), tumor recurrence (P = .038), and shorter recurrence-free survival (P = .046) compared with the partial loss of CDC14B. Conclusions: Microarray meta-analysis is a useful tool for pathologists. CDC14B expression is downregulated in ccRCC, suggesting its role in renal carcinogenesis. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS INC | - |
dc.subject | VON-HIPPEL-LINDAU | - |
dc.subject | PRIMARY CILIUM | - |
dc.subject | PROFILES | - |
dc.subject | CILIOGENESIS | - |
dc.subject | CONTRIBUTES | - |
dc.subject | PROGRESSION | - |
dc.subject | SURVIVAL | - |
dc.subject | HYPOXIA | - |
dc.subject | BIOLOGY | - |
dc.title | Loss of CDC14B Expression in Clear Cell Renal Cell Carcinoma Meta-Analysis of Microarray Data Sets | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Jung-Woo | - |
dc.contributor.affiliatedAuthor | Lee, Ju-Han | - |
dc.contributor.affiliatedAuthor | Kim, Young-Sik | - |
dc.identifier.doi | 10.1309/AJCP4PE4JPSRGBQS | - |
dc.identifier.scopusid | 2-s2.0-84899471393 | - |
dc.identifier.wosid | 000333070600017 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CLINICAL PATHOLOGY, v.141, no.4, pp.551 - 558 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CLINICAL PATHOLOGY | - |
dc.citation.title | AMERICAN JOURNAL OF CLINICAL PATHOLOGY | - |
dc.citation.volume | 141 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 551 | - |
dc.citation.endPage | 558 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.subject.keywordPlus | VON-HIPPEL-LINDAU | - |
dc.subject.keywordPlus | PRIMARY CILIUM | - |
dc.subject.keywordPlus | PROFILES | - |
dc.subject.keywordPlus | CILIOGENESIS | - |
dc.subject.keywordPlus | CONTRIBUTES | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | HYPOXIA | - |
dc.subject.keywordPlus | BIOLOGY | - |
dc.subject.keywordAuthor | Renal cell carcinoma | - |
dc.subject.keywordAuthor | Mete-analysis | - |
dc.subject.keywordAuthor | Microarray | - |
dc.subject.keywordAuthor | CDC14B | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.